Here’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
Leukemia and Lymphoma
A new report from Cardinal Health Specialty Solutions gives behind-the-scenes perspectives from oncologists about CAR-T cell therapies, biosimilars and AML therapies (or genomic medicines)
While CAR T-cell therapy has been proven to work for liquid—or blood—cancers, the challenge has been to apply this technology to solid tumors.
Transplant eligibility issues and drug regimen options raise difficult questions when treating older multiple myeloma patients.
CAR T-cell therapies and other immunotherapy give this oncologist’s cancer patients hope for a better quality of life.
Early detection of breast cancer continues to be the best way to save lives and decrease healthcare costs over time, and new technology could help.
Managing the care for members with cancer is unlike managing care for other chronic diseases. Here’s five ways to better care for cancer patients.
Experts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
As multiple myeloma treatment improvements continue, it’s important for managed care executives to get out in front of these 10 changes on the horizon.
Unique partnerships between payers and providers focus on keeping patients out of the hospital and on the road to remission.